Solriamfetol
| Solriamfetol | |
|---|---|
| Salts [] | |
|---|---|
| Solriamfetol hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 194.23 g/mol [1] |
| Predicted LogP | 0.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C10H14N2O2 |
| IUPAC name | [(2R)-2-amino-3-phenylpropyl] carbamate |
| SMILES | C1=CC=C(C=C1)C[C@H](COC(=O)N)N |
| InChI | InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1 |
| InChIKey | UCTRAOBQFUDCSR-SECBINFHSA-N |
| CAS number | 178429-62-4 |
| UNII | 939U7C91AI |
| PubChem CID | 10130337 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | ~7.1 hours |
| Metabolism | Minimal (~1%) |
| Excretion | Urine (95% unchanged) |
| Routes of administration | By mouth |
Solriamfetol (also known as (2R)-2-amino-3-phenylpropyl carbamate, Jzp-110, Ykp-10a, Adx-n-05, Skl-n-05, Benzenepropanol, β-amino-, carbamate (ester), (R)-, Benzenepropanol, β-amino-, carbamate (ester), (βR)-, R-228060, ((2R)-2-amino-3-phenylpropyl) carbamate or solriamfetolum) is a substance of the amphetamine class.
Chemistry
Salts []
Solriamfetol is typically found in the form of its hydrochloride salt.
Stereochemistry []
Solriamfetol is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Solriamfetol matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- centrally acting sympathomimetics (N06BA)
- solriamfetol (N06BA14)
Mechanism of action []
The specific mechanism of action is unknown but it may be through its activity as a dopamine and norepinephrine reuptake inhibitor. [1]
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 10130337, Solriamfetol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/10130337
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Solriamfetol. UNII: 939U7C91AI. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/939U7C91AI
Summary Basis of Decision (SBD) for Sunosi. Health Canada. 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00549&lang=en
Health product highlights 2021: Annexes of products approved in 2021. Health Canada. 3 August 2022. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html
Sunosi, Filmdragerad tablett 75 mg. FASS. September 2023. https://fass.se/health/product/20181109000031/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 12:01:21 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 12:01:17 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 12:01:17 |
| gsrs | ok | 2026-11-20 12:01:18 |
| hmdb | missing (no HMDB id) | 2026-11-20 12:01:17 |
| kegg | ok | 2026-11-20 12:01:20 |
| pubchem | ok | 2026-11-20 12:01:17 |
| missing (no r/tripreports posts mention it) | 2026-11-20 12:01:17 | |
| sider | missing (not in SIDER) | 2026-11-20 12:01:17 |
| structure | ok | 2026-11-20 12:01:17 |
| wikipedia | ok | 2026-11-20 12:01:18 |